Quick Answer
Immunocore Holdings plc reported Revenue From Contract With Customer Excluding Assessed Tax of $400.02 million for the year ending 2025.
- Immunocore Holdings plc showed an increase of +29.0% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from Immunocore Holdings plc's annual report (Form 10-K), filed with the SEC on February 25, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2024: $70.50 million | Q2 2024: $75.40 million | Q3 2024: $80.25 million | Q1 2025: $93.88 million | Q2 2025: $97.96 million | Q3 2025: $103.69 million.
- Over the full 5 years of available data (2021 to 2025), Immunocore Holdings plc's Revenue From Contract With Customer Excluding Assessed Tax has grown by 9,709.1%.
- Historical annual values: Fiscal year 2025: $400.02 million | Fiscal year 2024: $310.20 million | Fiscal year 2023: $249.43 million | Fiscal year 2022: $174.36 million | Fiscal year 2021: $4.08 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: